Results 31 to 40 of about 87,055 (290)

Effects of E/Z Configuration of Fluoroalkene-containing HDAC Inhibitors on Selectivity for HDAC Isoforms [PDF]

open access: yes, 2013
Histone deacetylase (HDAC) inhibitors belong to a new class of potential anticancer agents. It may be possible to reduce some of the toxicity by specifically targeting only the HDAC isoform.
Kiyota, Yuhei   +7 more
core   +1 more source

EVALUATION OF HISTONE DEACETYLASE INHIBITOR EFFECTS ON THYROID CANCER [PDF]

open access: yes, 2009
Histone deacetylases (HDACs) play a crucial role in the proper regulation of cellular functions through their connection with chromatin and transcriptional regulation.
Borbone, Eleonora
core   +1 more source

A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. [PDF]

open access: yesPLoS ONE, 2010
BACKGROUND: Lung cancer is the leading cause of cancer mortality worldwide, yet the therapeutic strategy for advanced non-small cell lung cancer (NSCLC) is limitedly effective.
Yen-An Tang   +8 more
doaj   +1 more source

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu   +11 more
wiley   +1 more source

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

open access: yesOncoImmunology, 2018
Checkpoint inhibitors targeting the PD-1/PD-L1 axis are promising immunotherapies shown to elicit objective responses against multiple tumor types, yet these agents fail to benefit most patients with carcinomas.
Kristin C. Hicks   +12 more
doaj   +1 more source

Human tumor cell lines exposed to Top1, HDAC, and dual Top1/HDAC inhibitors.

open access: yes, 2018
Human tumor cell lines exposed to Top1, HDAC, and dual Top1/HDAC inhibitors.
Raffaella Cincinelli (192154)   +12 more
core   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

open access: yesFEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta   +3 more
wiley   +1 more source

HDAC inhibitors as radiosensitizers [PDF]

open access: yes
Radiation therapy is one of the main anticancer therapies. However, there are considerable numbers of radioresistant carcinoma cells and severe adverse effects occasionally occur after radiation therapy.
Zhang, Yubin   +6 more
core   +2 more sources

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?

open access: yesMolecules, 2020
Histone deacetylase (HDAC) enzymes play crucial roles in epigenetic gene expression and are an attractive therapeutic target. Five HDAC inhibitors have been approved for cancer treatment to date, however, clinical applications have been limited due to ...
Joshua P. Smalley   +2 more
doaj   +1 more source

Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma

open access: yes, 2017
Hepatocellular carcinoma (HCC) is a frequent cause of cancer-related death; therefore, more effective anticancer therapies for the treatment of HCC are needed.
楊家榮;鄧哲明   +1 more
core   +1 more source

Home - About - Disclaimer - Privacy